TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02149407

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycerin
Description: Glycerin group GG will receive the 0.5 suppository (700 mg) twice daily for 48 hours. We will use the rounded part and discard the other part then will hold baby's buttocks for 2 minutes to ensure its delivery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rectal stimulation
Description: Rectal stimulation SG by soft cotton swab inserted to around 3 cm. The stick will press against the rectal wall in all direction for 2 minutes twice daily for 48 hours. Ky gel will be used to lubricate the stick and minimize direct friction to rectal wall.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Control group CG will receive routine NICU medical care without any specific intervention for the infant. The research nurse will do shame placebo twice daily by opening his diaper to blind the team for 2 minutes.
Study: NCT03603197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP-C1
Description: BP-C1, 0.05% solution for injection; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, solution for injection; doses: 0.07 mL/kg body weight intramuscularly once daily for 32 consecutive days
Study: NCT04206345

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise with blood flow restriction
Description: Elbow bending exercises with blood flow restriction will be performed to the exercise group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: Elbow bending exercises
Study: NCT05178823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthwash
Description: Comparison of oral rinses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine mouthwash
Description: Comparison of oral rinses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthwash
Description: Comparison of oral rinses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthwash
Description: Comparison of oral rinses
Study: NCT01834170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Two intratumoral injections of gemcitabine under endoscopic ultrasound (EUS)-guidance at month 0 and month 3.~The patients will receive systemic chemotherapy with or without radiotherapy at the discretion of oncologist
Study: NCT02876796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-0976
Description: Capsule(s) administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-0976
Description: Capsule(s) administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-0976
Description: Capsule(s) administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsule(s) administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsule(s) administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsule(s) administered orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1-13C acetate
Description: 10 g ± 0.25 g in 1000 mL 0.45% saline solution administered intravenously for 19 hours
Study: NCT04301895

Intervention type: DRUG
Group type: OTHER
Intervention: Remifentanil infusion
Description: 10 minute remifentanil infusion

Intervention type: DRUG
Group type: OTHER
Intervention: Remifentanil infusion
Description: 10 minute remifentanil infusion
Study: NCT03247868

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin+SPRInt
Description: Botulinum toxin injections in association with rehabilitative approach to cervical dystonia (SPRInt)
Study: NCT03447301

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Extra virgin olive oil (30mL daily)
Description: Intervention arm will take 30 mL of Extra virgin olive oil daily.
Study: NCT00033618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02876796

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1-13C acetate
Description: 10 g ± 0.25 g in 1000 mL 0.45% saline solution administered intravenously for 19 hours

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1-13C acetate
Description: 10 g ± 0.25 g in 1000 mL 0.45% saline solution administered intravenously for 19 hours

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fructose solution
Description: Fructose solution administered orally under fasted conditions immediately after study drug and every 30 minutes for a total of 20 doses

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fructose solution
Description: Fructose solution administered orally under fasted conditions immediately after study drug and every 30 minutes for a total of 20 doses

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fructose solution
Description: Fructose solution administered orally under fasted conditions immediately after study drug and every 30 minutes for a total of 20 doses
Study: NCT02083796

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Shoulder impingement_TSM
Description: A physiotherapist with 4 years of experience in manual therapy will administer the TSM targeting the middle thoracic spine of the subjects.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Asymptomatic_TSM
Description: A physiotherapist with 4 years of experience in manual therapy administered the TSM targeting the middle thoracic spine of the subjects.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Shoulder impingement_sham
Description: A physiotherapist with 4 years of experience in manual therapy administered the sham intervention targeting the middle thoracic spine of the subjects.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Asymptomatic_sham
Description: A physiotherapist with 4 years of experience in manual therapy administered the sham intervention targeting the middle thoracic spine of the subjects.
Study: NCT03361605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol administration
Study: NCT02713477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine/ lixisenatide fixed-ratio combination HOE901/AVE0010
Description: Pharmaceutical form: solution~Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine/ lixisenatide fixed-ratio combination HOE901/AVE0010
Description: Pharmaceutical form: solution~Route of administration: subcutaneous

Intervention type: DRUG
Group type: OTHER
Intervention: Insulin glargine HOE901
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study: NCT02343367

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral counseling
Description: Pediatrician trained in motivational interviewing techniques provides brief lifestyle behavioral counseling to child and parent using a Healthy Lifestyle Prescription

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: behavioral counseling
Description: Pediatrician trained in motivational interviewing techniques provides brief lifestyle behavioral counseling to child and parent using a Healthy Lifestyle Prescription
Study: NCT02713477

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study: NCT04457349

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Plasma Exchange (TPE)
Description: Treatment with Therapeutic Plasma Exchange (TPE)
Study: NCT02866032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOB015B

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclopirox 80 mg/g
Study: NCT02343367

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education Materials
Description: Health education materials about healthy eating and physical activity and a community resource guide

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education Materials
Description: Health education materials about healthy eating and physical activity and a community resource guide

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face to face counseling session
Description: 30 minute face-to-face family-centered behavioral counseling session delivered by a health educator

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messages
Description: regularly scheduled cell phone text messages for 12 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text messages
Description: regularly scheduled cell phone text messages for 12 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Counseling
Description: 14 telephone counseling sessions delivered by a health educator using motivational interviewing techniques. Two sessions per month for the first two months followed by one session per month for 10 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Newsletters
Description: 12 monthly newsletters mailed to participant homes
Study: NCT02653365

Intervention type: DEVICE
Intervention: Non-invasive ventilation
Description: Noninvasive ventilation (NIV) was performed with a noninvasive ventilator (BiPAP Synchrony®, Respironics Inc., Murrysville, PA, USA).
Study: NCT03333759

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alma - Harmony XL Laser
Description: The Erbium YAG laser at a 2940nm wavelength is used for ablative laser resurfacing as well as treating acne scars.
Study: NCT02164903

Intervention type: OTHER
Intervention: QoL Survey Booklet

Intervention type: OTHER
Intervention: QoL Survey Booklet
Study: NCT02899351

Intervention type: DEVICE
Intervention: Respiratory Volume Monitor
Study: NCT00582413

Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: Patient will fill out questionnaires, initial clinic visit, first post-surgery clinic evaluation and 3, 6, 12, 18 and 24 months following completion of all therapy.
Study: NCT03156192

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Survey
Description: Survey on the level of depression, quality of life, current and past music experiences, and perceived benefits of music in relation to psycho-social needs
Study: NCT01940432

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electroacupuncture group
Description: Procedure: electro-acupuncture;Points: Bilateral Zhong Liao (BL33) Hui Yang(BL35).Specially-made pad is stick on pierced acupoints. Bilateral BL33 are given acupuncture of 50一60mm with 30一45°angle to inward and downward by 75mm filiform needle. Bilateral BL35 are given acupuncture of 50一60mm to outward and upward by 75mm filiform needle. Twirl, lift and thrust for 3 times, until local sour and heavy feeling coming.The electric stimulator is applied to bilateral BL33 and BL35, with dilatational wave,50 Hz and electric current 1一5mA(milliampere).Every session lasts for 30 min per day.The participants are treated continuously for 8 weeks for 3 sessions a week, 24 sessions for each patient in all. The treatment is designed based on recent literature research in 10 years, former result and expert consensus.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pelvic floor muscle training group
Description: Procedure:first,identify anal sphincter/feel anus, and try to raise it from chair (without adding abdominal, thigh, and buttock muscles) with a position of sitting; second, identify levator ani and try to raise vagina from chair (without adding abdominal, thigh, and buttock muscles) with a position of Sitting, bent forward, elbows on knees; third, contract levator ani with a position of sitting, lying, and standing; fourth, contract anal sphincter with a position of sitting, lying, and standing. Length of Treatment and the treatment sessions are the same as treatment group.
Study: NCT01169012

Intervention type: DRUG
Group type: OTHER
Intervention: Clofarabine
Description: Intravenous Clofarabine (10mg/m2) Oral clofarabine (30mg/m2) Cimetidine (800mg)
Study: NCT03411083

Intervention type: PROCEDURE
Intervention: Total or unicompartmental knee replacement
Description: Fast-track Knee replacement surgery including same day surgery
Study: NCT04365231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine and azithromycin treatment
Description: hydroxychloroquine 10-day course of hydroxychloroquine 200 mg tablet three times a day. To be taken orally.~- azithromycin 5-day course of azithromycin 250 mg tablet twice a day on the first day of treatment, then once a day the 4 following days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional management of patients
Description: conventional management of patients

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional management of patients
Description: conventional management of patients
Study: NCT04116736

Intervention type: DEVICE
Intervention: ACUVUE® OASYS with Transitions™
Description: JJVC Marketed Contact Lens

Intervention type: DEVICE
Intervention: Silicone Hydrogel Contact Lens
Description: Any reusable spherical silicone hydrogel brand that is approved and marketed in the country conducting the study.
Study: NCT03574662

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Frailty assessment
Description: This assessment consists of a combination of gait speed measurement via infrared sensors as well as a grip strength assessment. Patients will then attend cardiac rehabilitation for an abbreviated six week program.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of life assessment
Description: This assessment consists of two questionnaires, Kansas City Cardiomyopathy Questionnaire and Minnesota Living with Heart Failure questionnaire. Patients will then attend cardiac rehabilitation for an abbreviated six week program.
Study: NCT01492153

Intervention type: DRUG
Intervention: biphasic human insulin
Description: NovoLet® device delivering human insulin. Selection of drug and timing of dose for each patient was at the discretion of the investigator

Intervention type: DRUG
Intervention: isophane human insulin
Description: NovoLet® device delivering human insulin. Selection of drug and timing of dose for each patient was at the discretion of the investigator

Intervention type: DRUG
Intervention: human soluble insulin
Description: NovoLet® device delivering human insulin. Selection of drug and timing of dose for each patient was at the discretion of the investigator
Study: NCT03635099

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (fasted)
Description: Placebo matching BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 25 mg (fasted)
Description: 25 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 50 mg (fasted)
Description: 50 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 100 mg (fasted)
Description: 100 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 200 mg (fasted)
Description: 200 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (fed)
Description: 4 film-coated tablets of matching Placebo were taken orally in the morning with a meal and 2 film-coated tablets of matching Placebo were taken orally in the evening with a meal for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 400 mg once daily (fed)
Description: 4 film-coated tablets of 100 milligram (mg) BI 730357 (400 mg in total) were taken orally in the morning with a meal and 2 film-coated tablets of matching Placebo were taken orally in the evening with a meal for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 200 mg twice daily, 400 mg total (fed)
Description: 2 film-coated tablets of 100 milligram (mg) BI 730357 were taken orally with a meal in the morning and evening (twice daily; total daily dosage: 400 mg) for 12 weeks.
Study: NCT02993185

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Your Move
Description: Your Move (YM) is an interactive sex education intervention. Groups of girls are randomly assigned to YM or Eat Smart (ES), a control interactive nutrition education intervention. Each program consist of seven 75-minute sessions, and each session contains 60 minutes of facilitator-led discussion, video clips, activities, and games as well as 15 minutes of personal reflection time during which girls practice the decision making skills they have learned. Participants complete online surveys about their attitudes, knowledge, and behavior related to food and nutrition and relationships and sex at baseline and also 3 months after the program ends.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Eat Smart
Description: Eat Smart (ES) is an interactive nutrition education intervention. Groups of girls are randomly assigned to ES or Your Move, an interactive sex education intervention. Each program consist of seven 75-minute sessions, and each session contains 60 minutes of facilitator-led discussion, video clips, activities, and games as well as 15 minutes of personal reflection time during which girls practice the decision making skills they have learned. Participants complete online surveys about their attitudes, knowledge, and behavior related to food and nutrition and relationships and sex at baseline and also 3 months after the program ends.
Study: NCT03724331

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Light Physical Activity 1
Description: Light (mild) physical activity program that corresponds with normal every day activities of daily living (\< 3.0 metabolic equivalents, METs), with a time commitment starting at 5 minutes a day 5 days a week gradually increasing to 30 minutes a day 5 days a week as you are able by week 6 as guided by your Registered Nurse researcher.~The program begins approximately within one week after discharge from the hospital with the physical activity program starting approximately within the first week post-discharge from the hospital.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Light Physical Activity 2
Description: Light (mild) physical activity program that corresponds with normal every day activities of daily living (\< 3.0 metabolic equivalents, METs), with a time commitment starting at 5 minutes a day 5 days a week gradually increasing to 30 minutes a day 5 days a week as you are able by week 6 as guided by your Registered Nurse researcher.~The program begins approximately within one week after discharge from the hospital with the physical activity program starting approximately 7 weeks post-discharge from the hospital.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Support Education Activity
Description: Participate in a supportive cancer-related education activity including a direct 10 - 15 minute phone conversation with a Registered Nurse researcher each week for 6-weeks after returning home from the hospital. Wear a pedometer each day of the study.~Recording pedometer steps in the daily diary each day.
Study: NCT04425590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLBS1033
Description: DLBS 1033 490 mg tablet 3 times daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 100 mg tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin 100 mg tablet once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Statin
Description: Atorvastatin 20 mg tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin
Description: Atorvastatin 20 mg tablet once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vit B12
Description: Vit B12 100 mg tablet three times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vit B12
Description: Vit B12 100 mg tablet three times daily
Study: NCT02521363

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KIBUR MICRODEVICE
Description: This device contains 16 reservoirs, each with a unique single agent or drug combination in microdose amounts of less than one millionth of a systemic patient dose. The device is implanted directly into the tumor during a biopsy procedure, and remains in situ for \~24 hours.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KIBUR MICRODEVICE
Description: This device contains 16 reservoirs, each with a unique single agent or drug combination in microdose amounts of less than one millionth of a systemic patient dose. The device is implanted directly into the tumor during a biopsy procedure, and remains in situ for \~24 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anthracycline and taxane based chemotherapy
Description: Conventional, standard of care neoadjuvant chemotherapy delivered irrespective of device readout
Study: NCT00669318

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alemtuzumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pentostatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sargramostim
Study: NCT00409279

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information, counseling and support
Description: individual-family consultation, support group, and ad hoc consultation
Study: NCT02822430

Intervention type: OTHER
Intervention: Pain scales
Description: * Visual analogic scale of pain~* Pain behaviour scale~* Short-FormHealth Survey (SF-36)~* Clinical Global impression~* Mini International Neuropsychiatric Interview (MINI)